Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Phase 2/3 Trial of the Efficacy and Safety of Intracerebroventricular Radioimmunotherapy Using 131I-omburtamab for Neuroblastoma Central Nervous System/Leptomeningeal Metastases

NCT03275402 is registered in ClinicalTrials.gov with Y-mAbs Therapeutics as lead sponsor.

NCT NCT03275402
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03275402 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Phase 2/3 Trial of the Efficacy and Safety of Intracerebroventricular Radioimmunotherapy Using 131I-omburtamab for Neuroblastoma Central Nervous System/Leptomeningeal Metastases
Lead sponsor
Y-mAbs Therapeutics
Phase
Phase 2/3
Overall status
Terminated
Start date
December 11, 2018
Completion date
June 2, 2023
Enrollment
52 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

cns metastases, leptomeningeal metastases, neuroblastoma